Through inhibition of the RAF/MEK/ERK and VEGF receptor tyrosine kinase signaling pathways, sorafenib has been shown to induce cell apoptosis, suppress cell proliferation, and inhibit tumor growth and angiogenesis in HCC cells (Liu et al., 2006). The gene discussed is RAF1; the disease is hepatocellular carcinoma.